Sai Life Sciences Ltd
SAILIFEBSE 544306PharmaceuticalsMkt cap ₹32,710 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹554 Cr
YoY +11.7%QoQ -7.9%
Net profit · Q1 FY27
₹73.29 Cr
YoY +21.2%QoQ -29.7%
Net margin · Q1 FY27
13.2%
+1.0 pts vs Q1 FY26
Net profit · FY26
₹349 Cr
YoY +105.1%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 554 | 602 | 556 | 537 | 496 | +11.7% |
| Other income | 3.54 | 15.52 | 8.38 | 15.33 | 9.90 | -64.2% |
| Total income | 558 | 618 | 565 | 553 | 506 | +10.2% |
| Profit before tax | 97.97 | 139 | 134 | 112 | 80.75 | +21.3% |
| Tax | 24.69 | 34.99 | 33.79 | 28.21 | 20.29 | +21.7% |
| Net profit | 73.29 | 104 | 100 | 83.84 | 60.46 | +21.2% |
| Net margin | 13.2% | 17.3% | 18.0% | 15.6% | 12.2% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | YoY |
|---|---|---|---|
| Revenue | 2,192 | 1,695 | +29.4% |
| Other income | 49.13 | 36.78 | +33.6% |
| Total income | 2,242 | 1,731 | +29.5% |
| Profit before tax | 466 | 228 | +104.7% |
| Tax | 117 | 57.57 | +103.7% |
| Net profit | 349 | 170 | +105.1% |
| Net margin | 15.9% | 10.0% |
BIC's take
We haven't covered Sai Life Sciences Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:10 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.